FREDERICK, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, is closely monitoring the recent declaration of a state of emergency in California due to the H5N1 bird flu outbreak. TOMI is dedicated to providing effective disinfection solutions to combat current and future pandemics, including H5N1.
Since April 2024, 61 cases of H5N1 bird flu have been reported in the United States, with the Centers for Disease Control and Prevention (CDC) confirming the first severe human case. The recent declaration of a state of emergency in California due to the H5N1 bird flu outbreak highlights the urgent need for effective disinfection and sanitation protocols.
SteraMist iHP cold plasma technology creates a powerful disinfectant that effectively kills a wide range of microorganisms, including viruses, bacteria, and fungi. It has been proven to be highly effective against avian influenza and other viruses. Studies with the USDA, Arkema, and well-known universities continue to prove the effectiveness of SteraMist cold plasma technology in the food industry.
“We understand the serious threat posed by H5N1 bird flu and other emerging diseases,” said Dr. Halden Shane, CEO of TOMI Environmental Solutions. “We are ready to deploy SteraMist to help protect public health and prevent the spread of H5N1. This outbreak demands serious attention and the implementation of powerful disinfection measures.”
SteraMist is committed to working with healthcare providers, government agencies, and other organizations to develop and implement comprehensive infection prevention and control strategies. By utilizing innovative technologies like SteraMist, we can help protect communities and mitigate the impact of future outbreaks.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve education sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…
Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other…
Beloved MedSpa Overcomes Devastating Fire and Challenges to Continue Serving the Bay Area SAN FRANCISCO,…
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage…
This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and…